PriceTargets.com logo

Flag Ship Acquisition - ETHZ Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$11.79 As of 12/4/2025 05:00 PM ET
▲ +0.46 (4.06%)

This chart shows the closing price for ETHZ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Flag Ship Acquisition Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ETHZ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ETHZ

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Flag Ship Acquisition in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $11.79.

This chart shows the closing price for ETHZ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 contributing investment analysts is to sell stock in Flag Ship Acquisition.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/14/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
7/29/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
7/12/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
6/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
6/11/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
5/24/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
5/10/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
4/24/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
4/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
3/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
3/7/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
2/19/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
2/1/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
1/18/2025Weiss RatingsReiterated RatingSell (E+)
10/20/2022Alliance Global PartnersInitiated CoverageBuy
5/9/2022Maxim GroupDowngradeBuy ➝ Hold
9/15/2021Maxim GroupInitiated CoverageBuy$41,800.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 2 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 1 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Flag Ship Acquisition logo
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $11.79
Low: $11.16
High: $11.82

50 Day Range

MA: $17.16
Low: $9.47
High: $25.80

52 Week Range

Now: $11.79
Low: $6.60
High: $174.60

Volume

546,563 shs

Average Volume

869,434 shs

Market Capitalization

$252.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Flag Ship Acquisition?

The following equities research analysts have issued reports on Flag Ship Acquisition in the last year: Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for ETHZ.

What is the current price target for Flag Ship Acquisition?

0 Wall Street analysts have set twelve-month price targets for Flag Ship Acquisition in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Flag Ship Acquisition in the next year.
View the latest price targets for ETHZ.

What is the current consensus analyst rating for Flag Ship Acquisition?

Flag Ship Acquisition currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe ETHZ will underperform the market and that investors should sell shares of Flag Ship Acquisition.
View the latest ratings for ETHZ.

What other companies compete with Flag Ship Acquisition?

Other companies that are similar to Flag Ship Acquisition include Cronos Group, Theravance Biopharma, Compass Therapeutics, Biohaven and ARS Pharmaceuticals. Learn More about companies similar to Flag Ship Acquisition.

How do I contact Flag Ship Acquisition's investor relations team?

Flag Ship Acquisition's physical mailing address is 3000 EL CAMINO REAL, BLDG 4, STE 200, PALO ALTO, CA, 94306. The company's listed phone number is (650) 507-0669 and its investor relations email address is [email protected]. The official website for Flag Ship Acquisition is 180lifesciences.com. Learn More about contacing Flag Ship Acquisition investor relations.